



## **Working Together To Ensure Australia Remains A Preferred Destination For Global Clinical Trials**

**By Dr Brendan Shaw  
Chief Executive, Medicines Australia**


17 October 2011

## **Clinical Trials Action Group – Recommendations**

- 1. Improve the timeliness of ethics and research governance review**
- 2. Provide cost recovery of efficient clinical trials**
- 3. Ensure that clinical trials can take advantage of Australia's developing e-Health system**
- 4. Improve patient recruitment**
- 5. Facilitate better co-ordination and greater collaboration among existing clinical trial networks**
- 6. Progress key clinical trial issues**

# Global Trends in Pharmaceutical R&D


## Global R&D Investment



Source: Pharmaceutical Research and Manufacturers of America, *Industry Profile*, 2011




## Clinical Trials - Global



Source: BCC Research, *The Clinical Trials Business*, 2011

# Clinical Trials in Australia

## Number of New Clinical Trials



Source: Therapeutic Goods Administration Half-Yearly Performance Report, July - December 2010, Clinical Trials (Medicines)

3 straight years of decline

is this an early sign that reforms are working?

## Ongoing Challenges

- No single body is responsible for ensuring Australia remains a preferred destination for global clinical trials
- Constrained financial resources – tight fiscal environment
- BUT all of the CTAG recommendations are progressing
- AND the Government just implemented the new R&D Tax Credit system, which will make conducting clinical trials in Australia up to 10% cheaper!

## Keeping Up The Momentum Is Extremely Important

**significant value to Australia remains at risk...**

**Approximately \$600 million is invested each year by industry in clinical trials.**

**This benefits:**



**Thank You**